Adult GlioblastomaPhase 1NCT04573140Papers
Autologous total tumor mRNA
RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
What the film says
This trial is for adults with glioblastoma that has come back or progressed after earlier treatment.
The idea: combine laser interstitial thermal therapy, an MRI guided laser procedure that heats the tumor, followed by lomustine, a chemotherapy pill.
This phase 1 study plans 25 patients. It looks at the safety of the combination and whether patients can complete it in the planned timeframe. At the University of California, Davis, Orwa Aboud leads it.
Public record; not medical advice.
Sources behind this film
Adults; recurrent/progressive glioblastoma; LITT, MRI guided laser, then lomustine by mouth; Phase 1; 25 patients; safety and feasibility in proposed timeframe; UC Davis; Orwa Aboud
The drug
The LITT procedure is performed per standard of care under general anesthesia using a stereotactic neurosurgical approach where a laser catheter is precisely inserted into the tumor under MRI guidance. Real-time MRI thermometry is used to ensure controlled tumor ablation while minimizing damage to adjacent structures.
Patients typically undergo postoperative MRI to assess treatment response, and most can be discharged within 24-48 hours, facilitating early initiation of adjuvant therapy. Approximately 7 days following LITT, lomustine is administered per standard of care on Day 1 for a total of one cycle. Participants will be monitored for serious and non-serious adverse events (AE) starting from initiation of LITT per institutional practices.
The study
This is a phase 1 study evaluating the safety and feasibility of laser interstitial thermal therapy (LITT) followed by lomustine (CCNU) for recurrent glioblastoma in adults. The primary aim is to evaluate the safety of the combination of LITT plus lomustine based on the assessment of treatment-related adverse events and the feasibility of completing LITT + lomustine in the proposed timeframe.
The secondary aim is to assess overall survival for up to 2 years after the first dose of lomustine.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.